GNH USA

Europe — EMA

Okrodin (Octreotide)

GNH USA supplies Okrodin (Octreotide), a peptide synthetic analog for acromegaly, neuroendocrine tumor symptoms and variceal bleeding.

Octreotide

Request sourcing

1
Pack/s

What is Octreotide?

Octreotide, the active ingredient in Okrodin, is a peptide synthetic analog presented as an injectable solution for subcutaneous use. It is employed to control hormone‑related disorders such as acromegaly and neuroendocrine tumor symptoms in adult patients. GNH USA supplies Okrodin as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

What is Octreotide used for?

Okrodin (octreotide) acts on the somatostatin pathway to manage several endocrine and gastrointestinal conditions. - Acromegaly: reduces growth hormone secretion and associated tissue overgrowth. - Neuroendocrine tumors: controls hormone‑related flushing and diarrhea. - Carcinoid syndrome: diminishes severe flushing and watery diarrhea. - VIPoma: alleviates profuse watery diarrhea and electrolyte loss. - Acute variceal bleeding: lowers portal pressure to help control bleeding.

What are the side effects of Octreotide?

Octreotide may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Abdominal pain: cramping or discomfort. - Diarrhea: loose stools, often transient. - Injection site reactions: redness or swelling. - Hyperglycemia: elevated blood glucose levels. - Gallstones: biliary sludge formation.

Serious or Rare Side Effects: - Severe hyperglycemia or hypoglycemia: requires medical attention. - Cardiac arrhythmias: irregular heart rhythms. - Acute pancreatitis: sudden abdominal pain with elevated enzymes. - Severe allergic reactions: rash, itching, swelling, or anaphylaxis.

What precautions apply to Octreotide?

Before initiating Okrodin, consider the following safety measures. - Glucose monitoring: assess blood sugar regularly, especially in diabetic patients. - Gallbladder evaluation: monitor for biliary sludge or stones during long‑term therapy. - Cardiovascular assessment: watch for bradycardia or arrhythmias. - Renal function: adjust use in patients with severe renal impairment. - Pregnancy and lactation: use only if clearly needed; discuss risks with a healthcare professional. - Store at ambient temperature: keep below 25°C, retain in original packaging, protect from moisture and direct sunlight.

What does Octreotide interact with?

Octreotide can affect the activity of several concomitant medicines.

Major Interactions (Avoid): - Cyclosporine: may increase cyclosporine blood levels, raising toxicity risk. - Diazoxide: can diminish octreotide’s glucose‑lowering effect. - Bromocriptine: may reduce therapeutic efficacy of octreotide.

Moderate Interactions (Monitor Closely): - Insulin and oral hypoglycemics: enhanced hypoglycemic effect; monitor glucose. - Other somatostatin analogs: additive hormonal suppression; watch for side effects. - Warfarin: potential alteration of anticoagulation; check INR regularly.

Frequently asked questions

What conditions is Okrodin used to treat?+
Okrodin (octreotide) is prescribed for hormone‑related disorders such as acromegaly, symptom control in neuroendocrine tumors, carcinoid syndrome, VIPoma‑induced diarrhea, and acute variceal bleeding. It works by mimicking somatostatin to suppress excess hormone secretion.
How does octreotide work in the body?+
Octreotide binds to somatostatin receptors, especially subtype 2, on endocrine and gastrointestinal cells. This binding blocks the release of several hormones—including growth hormone, insulin, and gastrointestinal peptides—and reduces splanchnic blood flow, thereby controlling disease‑related symptoms.
What is the usual dose of Okrodin?+
The specific dose of Okrodin is determined by the prescribing clinician based on the patient’s condition, severity, and response to therapy. Healthcare professionals tailor the regimen to achieve optimal clinical outcomes while monitoring safety.
Is Okrodin safe during pregnancy or breastfeeding?+
Okrodin should be used during pregnancy or lactation only if the potential benefit justifies the potential risk to the fetus or infant. Clinicians must evaluate each case individually and discuss possible effects with the patient.
How do I order Okrodin from GNH USA?+
To request Okrodin, submit an enquiry on the product page at gnh-usa.com, specifying the required quantity. GNH USA works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and import documentation.
How does Okrodin compare with other somatostatin analogs?+
Okrodin (octreotide) shares the same mechanism as other somatostatin analogs like lanreotide, but differences may exist in formulation, dosing frequency, and approved indications. Clinicians choose based on patient convenience, specific regulatory approvals, and individual response profiles.
What are the storage requirements for Okrodin?+
Okrodin should be stored at ambient temperature, below 25 °C. Keep the product in its original packaging, protect it from moisture and direct sunlight, and avoid freezing to maintain stability.
How is Okrodin administered?+
Okrodin is supplied as an injectable solution for subcutaneous (or intravenous) administration. The injection is typically performed by a healthcare professional using aseptic technique, following the dose prescribed by the treating physician.
What are the most serious risks associated with Okrodin?+
Serious risks include severe hyperglycemia or hypoglycemia, cardiac arrhythmias, acute pancreatitis, and rare allergic reactions such as anaphylaxis. Patients should be monitored closely for these events, especially during the initiation of therapy.
Who should not use Okrodin?+
Okrodin is contraindicated in patients with known hypersensitivity to octreotide or any of its excipients. Caution is advised for individuals with uncontrolled diabetes, severe cardiac conduction disorders, or significant gallbladder disease.
Information provided on this page is for educational use by procurement and clinical professionals. Always consult a licensed healthcare provider for medical advice and prescribing decisions. GNH USA supplies this product subject to applicable regulatory and licensing requirements.
Send a sourcing enquiry for this product →

Product details

Drug
Octreotide
Route
Intramuscular Use
Manufacturer
Pharmathen S.A.
Origin
EU

Related products

Mycapssa 20 mg/1

Mycapssa 20 mg/1

Octreotide · 20 mg

Mycapssa
CAPSULE, DELAYED RELEASE
Chiesi USA, Inc.
USA
Octreo

Octreo

Octreotide

Ratiopharm Gmbh
EU
Octreoteva Long Acting

Octreoteva Long Acting

Octreotide

Teva B.V
EU
Octreotid Bendalis

Octreotid Bendalis

Octreotide

Bendalis Gmbh
EU